Namir Hassan

Company: Zelluna Immunotherapy

Job title: CEO

Seminars:

Keynote Panel Discussion – Driving Clinical Success in Solid Tumor Settings 10:00 am

What is the optimal cell type to tackle the solid tumor microenvironment What solid tumors should the field be targeting first, considering myeloid compartments and heterogeneity? Address acquired versus inherent resistance to immunotherapy Discuss how different modalities induce epitope spreading and the potential of this to overcome heterogeneityRead more

day: Day One